Figure 3.

Swimmer plot of patient treatment course following bevacizumab initiation. Bev: Bevacizumab. First bevacizumab treatment was assigned to time 0 months. All patients remain alive as of March 2023. Patient ID is consistent with patient ID in all other tables and figures. We define “rebound” as greater than 20% volume change in VS volume following bevacizumab discontinuation, partial response as greater than 25% volume reduction on volumetric assessment, stable disease as less than 25% volume change on volumetric assessment, and progressive disease as greater than 25% volume increase on volumetric assessment.